These results indicated that rapamycin could dramatically inhibit the Escherichia-Shigella- and Enterobacteriaceae-derived LPS-induced NSCLC cell proliferation by suppressing the mTOR-NF-κB axis. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.